Baxter International Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 31, 2019, reports the issuance of an earnings press release for Baxter International Inc. The release covers the quarterly and twelve-month periods ended December 31, 2018. The filing serves to disseminate financial results and non-GAAP measures to investors.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing these figures. The document defines the following non-GAAP metrics used in the report:
- Adjusted Income Measures: Includes adjusted income from continuing operations, adjusted diluted earnings per share, adjusted operating income, and adjusted pre-tax income, all excluding special items.
- Adjusted Expenses: Includes adjusted marketing and administrative expenses, adjusted research and development expenses, and adjusted income tax expense.
- Sales Metrics: Net sales are presented on a constant currency basis (excluding foreign exchange rate changes) and an operational basis.
- Free Cash Flow: Defined as operating cash flow less capital expenditures.
Material Changes and Adjustments
The filing details specific adjustments made to operational sales to facilitate period-over-period comparisons:
- Quarter Ended December 31, 2018: Operational sales exclude the impact of foreign exchange, generic competition for U.S. cyclophosphamide, and the acquisition of RECOTHROM and PREVELEAK products.
- Full Year 2018: Operational sales exclude seven months of sales from the Claris Injectables business acquired in July 2017.
- Special Items: Excluded from adjusted measures are items deemed highly variable, difficult to predict, or unusual, including intangible asset amortization.
Management Commentary and Risks
Management utilizes these non-GAAP measures for internal financial planning, monitoring business unit performance, assessing peer performance, and determining incentive compensation. The filing includes the following cautions:
- Non-GAAP measures are not substitutes for GAAP financial information.
- Special items included in adjustments are based on estimates; future events may result in different actual results.
- Non-GAAP measures used by Baxter may differ from similar measures used by other companies.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures.
- Verify the reconciliation between non-GAAP measures and the most directly comparable GAAP measures.
- Assess the magnitude of "special items" excluded from adjusted earnings.
- Confirm the impact of the Claris Injectables acquisition on full-year operational sales comparisons.
- Examine the specific impact of generic competition on U.S. cyclophosphamide sales.